Mirion Technologies heads into its third-quarter report with an unusual split personality. Its order book has never looked healthier, with backlog above $1.1 billion and nuclear power orders excluding acquisitions up 50% last quarter, yet organic revenue barely moved, rising just 1%. Management has reaffirmed full-year guidance three quarters running while leaning on a steep second-half ramp. This report, due after the close on October 27, is the first real chance to see whether that ramp is arriving or slipping again.
Wall Street expects earnings of $0.12 per share on revenue of $277.9 million. The revenue figure implies growth of roughly 25% from a year ago, but most of that comes from acquisitions, including Paragon, rather than from the core business. The more telling number is EPS growth of only about 9%, a gap that reflects Paragon's drag on profitability and management's own warning that nuclear safety margins would contract in the third quarter on dilution and mix. For the full year, the company still guides to $0.48 to $0.55 per share on $1.13 billion to $1.15 billion in revenue. Consensus sits at $0.53 and $1.14 billion, squarely in the middle of the sales range but in the upper half for earnings. That leaves the Street assuming margin progress continues even as the business has to deliver second-half organic growth of roughly 7.5% to 11.2%.
The central question is conversion. Mirion said it booked more than $50 million in large orders in the first two weeks of July, and small modular reactor orders jumped to $49 million in the second quarter. Management described the SMR timeline as moving earlier and called itself increasingly bullish. Validation would look like nuclear power revenue finally turning positive organically after a flat second quarter, sequential order growth that holds up, and a backlog that keeps climbing despite shipments. A challenge would be another quarter of slipping large-order timing, which management admitted had burned it in the second quarter, or any sign that a government shutdown is delaying Department of Energy business. The surprise debook of an old China new-build order and shrinking wallet share there also mean any further China cancellations would hit a sensitive nerve.
The medical side is where the guidance math gets fragile. Last quarter Mirion cut its nuclear medicine outlook to mid-single-digit growth from double digits and moved dosimetry to a decline, offset by raising radiation therapy quality assurance to double-digit organic growth. If medical stabilizes and RTQA keeps its momentum, the reaffirmed outlook looks credible. Another medical shortfall, especially in hardware, would put more pressure on the nuclear business to carry a fourth quarter that already requires mid-teens growth in nuclear safety. Free cash flow is the quieter bright spot; a first-half total of $60 million was the best since the company went public, and management pointed toward the high end of its second-half range.
The market has not been generous. Shares have fallen about 13% since the last report while the S&P 500 gained roughly 3%, and at $15.15 the stock trades well below its 200-day moving average near $18.77 and closer to its post-earnings low of $14.04 than its high of $17.65. Sentiment has nonetheless softened from heavily bearish to only mildly so, suggesting skeptics have already priced in some disappointment.
Ultimately, this quarter turns on whether Mirion can show that its swelling nuclear backlog is translating into revenue on schedule. If organic growth visibly accelerates and medical holds steady, a fourth straight reaffirmation could finally feel conservative. If timing slips again, the gap between a booming order book and a flat income statement will become the story.